Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cynthia Robinson

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
NPJ Vaccines|November 30, 2022
Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against EbolaViki Bockstal, Maarten Leyssen, Dirk Heerwegh, et al.
Frontiers in Immunology|September 20, 2023
Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humansChelsea McLean, Karin Dijkman, Auguste Gaddah, et al.
Nature Medicine|September 8, 2025
Heterologous two-dose Ebola vaccine regimen in pregnant women in Rwanda: a randomized controlled phase 3 trialJulien Nyombayire, Rosine Ingabire, Amelia Mazzei, et al.
Vaccines|February 24, 2024
Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational StudyAdeep Puri, Andrew J Pollard, Catherine Schmidt-Mutter, et al.
Plos One|October 5, 2022
First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled studyViki Bockstal, Georgi Shukarev, Chelsea McLean, et al.
The Lancet. Infectious Diseases|November 20, 2020
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trialAndrew J Pollard, Odile Launay, Jean-Daniel Lelievre, et al.
Plos Medicine|January 11, 2022
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trialZacchaeus Anywaine, Houreratou Barry, Omu Anzala, et al.
Plos Medicine|October 29, 2021
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in AfricaHoureratou Barry, Gaudensia Mutua, Hannah Kibuuka, et al.
Emerging Infectious Diseases|February 24, 2022
Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra LeoneDaniela Manno, Philip Ayieko, David Ishola, et al.
Ebiomedicine|April 26, 2023
Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratoryChelsea McLean, Houreratou Barry, Mark Kieh, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
NPJ Vaccines|November 30, 2022
Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against EbolaViki Bockstal, Maarten Leyssen, Dirk Heerwegh, et al.
Frontiers in Immunology|September 20, 2023
Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humansChelsea McLean, Karin Dijkman, Auguste Gaddah, et al.
Nature Medicine|September 8, 2025
Heterologous two-dose Ebola vaccine regimen in pregnant women in Rwanda: a randomized controlled phase 3 trialJulien Nyombayire, Rosine Ingabire, Amelia Mazzei, et al.
Vaccines|February 24, 2024
Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational StudyAdeep Puri, Andrew J Pollard, Catherine Schmidt-Mutter, et al.
Plos One|October 5, 2022
First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled studyViki Bockstal, Georgi Shukarev, Chelsea McLean, et al.
The Lancet. Infectious Diseases|November 20, 2020
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trialAndrew J Pollard, Odile Launay, Jean-Daniel Lelievre, et al.
Plos Medicine|January 11, 2022
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trialZacchaeus Anywaine, Houreratou Barry, Omu Anzala, et al.
Plos Medicine|October 29, 2021
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in AfricaHoureratou Barry, Gaudensia Mutua, Hannah Kibuuka, et al.
Emerging Infectious Diseases|February 24, 2022
Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra LeoneDaniela Manno, Philip Ayieko, David Ishola, et al.
Ebiomedicine|April 26, 2023
Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratoryChelsea McLean, Houreratou Barry, Mark Kieh, et al.
Pageof 5